[ad_1]
WASHINGTON (ANTARA) – The maker of the experimental drug corona remdesivir virus, Gilead Sciences Inc., said Thursday it will have international partners to boost production of potential drugs for COVID-19.
The company said it still expects to be able to produce more than a million remdesivir medicines by December, “and plans to produce several million medicines by 2021.”
Until the end of next month, Gilead claimed to have to produce more than 140,000 drugs, which are administered through infusions in hospitals.
More patients can be treated if the drug works in a shorter time than normal in 10 days, Giliead said.
The United States Food and Drug Administration (FDA) said Gilead was discussing the availability of remdesivir for patients as soon as possible.
Also read: Gilead: Remdesivir cures patients with COVID-19 if given before
The National Institute of Health on Wednesday (4/29) said preliminary results from the remdesivir trial showed that among COVID-19 patients who received the drug, 31 percent recovered faster than those who received a placebo.
In a trial of 1,063 patients, patients who took the drug made by Gilead recovered in 11 days compared to 15 days in those who received the placebo.
While the data will require a lot of analysis to find out how effective the drug remdesivir is for patients with COVID-19, US health officials. USA They praise the drug as a very important drug because it influences diseases that currently have no cure or vaccine.
Data from a trial by Gilead, also revealed Wednesday, showed a similar clinical cure for patients with severe symptoms of COVID-19, regardless of whether they received the drug within 5 or 10 days.
Also read: WHO is reluctant to comment on remdesivir reports on COVID-19 treatment
More detailed results from US studies are expected next month. There are also a number of other studies, which also examine the use of remdesirvir for the treatment of coronavirus.
On Thursday, the European Medical Agency said it had started a “rolling review” of data on the use of the antiviral drug Gilead for the treatment of COVID-19, a disease caused by a highly contagious virus.
Rotary reviews are one of the regulatory tools available to the agency to help accelerate the interpretation of promising experimental medications during public health emergencies.
Source: Reuters
Also read: UGM professor urges the public to carefully choose alternative medicines COVID-19
Also read: India allows export of anti-malaria drugs after Trump files his application
Indonesia Strengthens Multilateralism for Access to COVID-19 Vaccine
Translator: Asri Mayang Sari
Publisher: Tia Mutiasari
COPYRIGHT © BETWEEN 2020
